Drugs / SSS39
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07057726 | Oct 2024 → Oct 2025 overdue | — | Shenyang Sunshine Pharmaceutical Co., LTD. | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SSS39 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07057726 ↗ |
| Route | Intravenous | “Single intravenous infusion” NCT07057726 ↗ |